Episodes (Page 7)
✨
Israel aims to be a global pharma R&D hub with AI-driven startups.
Mati Gill
✨
Step Pharma targets blood cancers and solid tumors by inhibiting CTSP1.
Andrew Parker
✨
Lilly's Centessa acquisition and Apellis's capabilities for Biogen are discussed.
✨
Lilly's Centessa acquisition and Apellis's capabilities for Biogen are discussed.
✨
China releases new guidelines for CAR-T therapies, signaling regulatory evolution.
✨
UK medtech regulatory system needs alignment with the EU.
✨
Merck pushes Terns and other deals; Boehringer warns on Europe's innovation climate.
✨
Longevity is emerging as a significant OTC commercial opportunity.
Magda Starula
✨
Merck pushes Terns and other deals; Boehringer warns on Europe's innovation climate.
✨
Reviewing FDA Commissioner Martin Makary's first year and key policy accomplishments.
✨
Lupin's strategy for first-in-class and best-in-class assets, including GLP-1 agonists.
Nilesh Gupta
Vinita Gupta
✨
Many blockbuster drugs are expected to lose market dominance this year.
✨
Many blockbuster drugs are expected to lose market dominance this year.
✨
Judge halts ACIP reconstitution, potentially violating law; next steps considered.
Bridget Silverman
✨
CDMO Morpho details custom vaccine development from concept to manufacturing.
Court Turner
Lev Becker
✨
Investor interest in early-stage neuroscience funding is growing.
✨
AAM's Access! 2026 conference in Miami and Medicines for Europe's regulatory conference in Amsterdam were covered.
✨
Probiotics market is fast-growing but fragmented with complex claims.
David Pineda Ereno
✨
Roche's giredestrant trial setback and BioNTech founder's exit were highlighted.
✨
Roche's giredestrant Phase III trial faced a setback.